Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Bibliographic Details
Main Authors:	Berna Akıncı Özyürek, Yurdanur Erdoğan, Nilgün Yılmaz Demirci, Sertaç Büyükyaylacı Özden, Tuğçe Şahin Özdemirel
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2016-04-01
Series:	Eurasian Journal of Pulmonology
Online Access:	http://www.journalagent.com/z4/download_fulltext.asp?pdir=eurasianjpulmonol&plng=eng&un=EJP-96268

Similar Items

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Is pirfenidone effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres, et al.
Published: (2017-03-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?
by: I. Galal
Published: (2014-10-01)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
by: Ulrich Costabel, et al.
Published: (2019-03-01)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
by: Lisa H. Lancaster, et al.
Published: (2017-12-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience
by: Esam H Alhamad
Published: (2015-01-01)

June 2014 Tucson pulmonary journal club: pirfenidone in idiopathic pulmonary fibrosis
by: Alzoubaidi M, et al.
Published: (2014-10-01)

Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models
by: Wencheng Yu, et al.
Published: (2017-01-01)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
by: Manon Belhassen, et al.
Published: (2021-05-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
by: Carlos Aravena, et al.
Published: (2015-01-01)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?
by: S. Campainha, et al.
Published: (2016-03-01)

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena
by: Lucia Vietri, et al.
Published: (2020-02-01)

Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis
by: Gulati S, et al.
Published: (2020-05-01)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2018-01-01)

Correction: Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
by: Carlos Aravena, et al.
Published: (2015-01-01)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
by: Sahajal Dhooria, et al.
Published: (2015-01-01)

Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
by: Ramadan M Nafee, et al.
Published: (2019-01-01)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
by: Sakayori M, et al.
Published: (2019-07-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
by: Antje Prasse, et al.
Published: (2019-07-01)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
by: Yukari Satsuma, et al.
Published: (2020-11-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
by: Yasuhiko Koga, et al.
Published: (2019-05-01)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
by: Vincent Cottin, et al.
Published: (2015-03-01)

Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
by: Myung Jin Song, et al.
Published: (2021-05-01)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
by: C. C. Moor, et al.
Published: (2020-07-01)

Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
by: Lina Marcela Barranco-Garduño, et al.
Published: (2020-10-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01)

Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis
by: Al-Ansari Shehab, et al.
Published: (2020-06-01)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021-08-01)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
by: Anastasia Y Ipatova, et al.
Published: (2019-03-01)

Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
by: Amal A.E.-A Sadon, et al.
Published: (2020-01-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

rs2076295 variants influence nintedanib and pirfenidone outcomes in idiopathic pulmonary fibrosis: a pilot study
by: Martina Doubkova, et al.
Published: (2021-09-01)

Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis—A Six-Month Follow-Up Study in Patients Treated with Pirfenidone
by: Kaja Jaskiewicz, et al.
Published: (2020-08-01)